Kalbe Farma - Resilient Growth Outlook at Reasonable Valuation
Unbranded Generic and distribution to drive FY24F top line, while CH and Nutrition revenue normalized. We raised FY24-25F NP by 4.5-2.9%
204 Views
Kalbe Farma (KLBF.IJ) - Resilient Growth Outlook at Reasonable Valuation
Unbranded Generic and distribution to drive FY24F top line, while CH and Nutrition revenue normalized We raised FY24-25F NP by 4.5-2.9%, driven by...
232 Views
CrossASEAN Indonesia Strategy - Parting Clouds
The Indonesian stock market was down 2% over the last year despite a flurry of inflows in the summer but this year looks interesting with a new...
504 Views
Indonesia Strategy - Caught in a Perfect Updraft?
Despite the JCI knocking on all-time highs, valuations continue to look attractive with prospects of a better 2H2024 and lower interest rates. Top...
483 Views
Consumer: 4Q24 Earnings Outlook: ICBP and INDF to Be Robust, SIDO Eyes Upside
We estimate that the Indofood group still reported strong net profit in FY24, while SIDO may exceed consensus expectations.
182 Views